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Abstract 
Purpose: To determine the prevalence of extended spectrum beta lactamase (ESBL) producing Gram 
negative bacteria causing wound and urinary tract infections among in- and out-patients in a tertiary 
health facility.   
Methods: The presence of ESBL was determined among 230 Gram negative bacilli isolated from 
wound (105) and urine (125) specimens from in- and out-patients who attended University of Benin 
Teaching Hospital (UBTH) for treatment using the double disc synergy method. Disc susceptibility test 
was performed on all isolates using standard techniques.  
Results: There was no significant difference in the prevalence of ESBL production between isolates 
from wound (47.6 %) and urine (41.6 %) as well as between in-patients (48.8 %) and out–patients 
(39.38 %). Enterobacter species were the most prevalent producers of ESBL from both wound and 
urine specimens as well as from both in- and out–patients. Bacterial isolates that produced ESBL were 
more resistant to amoxicillin-clavulanate, ceftazidime, ceftriaxone, cefotaxime, gentamicin, ciprofloxacin 
and ofloxacin compared to non-ESBL producers.  
Conclusion: A high prevalence (44.3%) of ESBL producing Gram–negative bacteria was observed 
among the patients, with Enterobacter species being the most prevalent. Prudent use of antibacterial 
agents is advocated to stem the tide.  
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Antibiotic resistance of bacteria is commonly 
seen in daily medical practice with multi-drug 
resistant Gram negative bacteria posing the 
greatest threat to human health [1]. Beta lactam 
antibiotics are the most predominantly prescribed 
antibiotics to treat bacterial infections, especially 
in Nigeria hospitals [1,2]. β-lactamases are major 
defense of Gram negative bacteria against β-
lactam antibiotics [3]. Extended spectrum β-
lactamases (ESBL), a type of β-lactamase, are 
typically inhibitor-susceptible β-lactamase that 
hydrolyze penicillins, cephalosporins and 
aztreonam [3], and are encoded by mobile gene 
[4]. These genes often code resistance to 
cephalosporins and other antibiotics such as 
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Infections caused by ESBL-producing Gram 
negative bacteria are associated with increased 
morbidity and mortality which is linked to 
inappropriate or delayed antimicrobial treatment 
[6]. Risk factors that have been associated with 
ESBL production include old age  (> 65 years), 
male gender, previous use of β-lactam antibiotics 
and fluoroquinolones amongst others [6,7]. In 
Nigeria, extended–spectrum cephalosporins and 
fluoroquinolones are widely used as broad–
spectrum antibiotics and remain the drugs of 
choice to treat infections caused by various 
Gram negative pathogens [8]. Also, antibiotics 
use in Nigeria is unregulated and over the 
counter sales of antibiotics without prescriptions 
are rife [9-11]. These indicate that ESBL 
producing organisms may be rife in Nigeria and 
indeed reports of ESBL–producing Gram 
negative bacteria exists [11].  
 
A previous study from Benin City, Nigeria 
reported a prevalence of 2.7 % of ESBL 
producing Gram negative bacteria from blood 
stream infections and surgical wounds [12]. 
However, that study, only evaluated ceftazidime 
as the only indicator of ESBL production. 
Ceftazidime is a good indicator of TEM 
(Temoniera) and SHV  (Sulphydryl) type of ESBL 
and not the CTX–M (Cefotaximase – Munich) 
type [13]. The CTX–M type is detected with the 
use of cefotaxime [13]. It has been reported that 
Gram–negative bacteria cause a significant 
number of infections in Nigerian hospitals and 
represent the majority of both wound and urinary 
isolates, which form the largest group of 
specimens received in microbiology laboratories 
[11]. These will indicate that the study of 
Omoregie et al [12], may have underestimated 
the true prevalence of ESBL. Against this 
background, this study aimed to determine the 
prevalence of ESBL among Gram negative 
bacteria causing wound and urinary tract 
infections among community and hospital 
isolates. The susceptibility patterns of all the 




Bacterial isolates  
 
A total of 230 consecutive non–repetitive 
bacterial isolates from wound (105) and urinary 
tract infections  (125) collected from patients 
attending University of Benin Teaching Hospital, 
Benin City  (UBTH) were used for this study. One 
hundred and twenty three (123) of these isolates 
were recovered from in–patients while 107 
isolates were from out–patients. The isolates 
included Escherichia coli, Klebsiella species, 
Citrobacter species, Enterobacter species, 
Proteus mirabilis, Proteus vulgaris, Providencia 
species, Acinetobacter species and 
Pseudomonas aeruginosa. All isolates were 
identified using standard techniques [14].  
 
ESBL detection  
 
The presence of ESBL was detected in all 
isolates using the double disc test [13]. Briefly, 
test organisms were emulsified in sterile water 
and the turbidity matched with 0.5 McFarland 
standards. Once matched, a sterile cotton wool 
swab was dipped in the organism suspension 
and excess liquid was removed by turning the 
swab on side of the test tube. The entire surface 
of Mueller–Hinton agar plate was seeded by 
swabbing in three directions with the swab. A 
disc containing 30 µg amoxicillin–clavulanate 
(Oxoid, England) was placed at the centre of the 
agar plate. A 30 µg ceftazidime disc (Oxoid, 
England) was placed 25 mm from the 
amoxicillin–clavulanate disc and another disc 
containing 30 µg cefotaxime (Oxoid, England) 
was placed on the opposite side of the 
amoxicillin–clavulanate disc  (25 mm apart). The 
plates were incubated at 37 oC overnight and 
ESBL production was inferred as positive if there 
was an expansion of the zone of inhibition 
between the ceftazidime and amoxicillin–
clavulanate disc, cefotaxime and amoxicillin–
clavulanate disc or both.  
 
Disc susceptibility testing  
 
Disc susceptibility tests were performed on all 
bacterial isolates using the British Society for 





The data obtained were analyzed with chi square 
(X2) test and odd ratio analysis using the 
statistical software Instat (R) (Graph Pad 




A total of 102 (44.3 %) out of the 230 isolates 
produced ESBL. Of these isolates that were 
positive for ESBL, 97 (95.1 %) were indicated by 
both ceftazidime and cefotaxime, while 5 (4.9 %) 
were indicated by cefotaxime alone. Generally 
and among individual isolates (with the exception 
of Citrobacter species), there was no significant 
difference in EBSL production among isolates 
from wounds and urinary tract infections. EBSL 
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production by Citrobacter species was more 
likely to occur from the bacteria isolated from 
wounds as compared to urinary tract infections. 
(OR = 55.000, 95 % CI = 0.828, 3654.5, p = 
0.0476). Enterobacter species were the most 
prevalent producers of ESBL generally whether 
from wound, and urine specimens (Table 1). 
 
Isolates of Enterobacter species from both in–
patients and out–patients were the most 
predominant producers of ESBL in comparison to 
other isolates. Although Gram negative isolates 
from in–patients  (48.8 %) had higher prevalence 
of ESBL production than others recovered from 
out–patients  (39.3 %) and were more likely to 
produce ESBL  (OR = 1.474, 95 % CI = 0.872, 
2.492); this was not statistically significant (P = 
0.1833) (Table 2).  
 
The susceptibility profiles of ESBL–producing 
and non–ESBL–producing Gram negative 
bacterial isolates are shown in Table 3 and 4 
respectively. Generally, isolates that produce 
EBSL were more resistant to the antimicrobials 
used compared with non–ESBL producers. 
Imipenem was the most active antibiotic against 
ESBL–producing and non–ESBL–producing 




Of the 102 Gram negative bacteria that produced 
ESBL, 97 (95.1 %) were detected by both 
ceftazidme and cefotaxime. This will indicate that 
majority of the isolates producing ESBL in this 
study produce multiple types of ESBL such as 
TEM, SHV and CTX–M types. Indeed previous 
studies have reported both TEM, SHV and CTX–
M types of ESBL in Nigeria [8,17]. Five isolates 
(4.9 %) produced only CTX–M type. This 
indicates that the CTX–M type of ESBL were 
more predominant in this study and agrees with 
previous reports from other Nigerian studies  
 
Table 1: Prevalence of ESBL production in relation to specimen 
   









No. tested No. positive 
(%) 
Escherichia coli 25 12 (48.0) 54 24 (44.4) 79 36 (45.6) 
Klebsiella  species  25 14 (56.0) 23 7 (30.4) 48 21 (43.8) 
Citrobacter species*  2 2 (100.0) 5 0 (0.0) 7 2 (28.6) 
Enterobacter species  1 1 (100.0) 8 7 (87.5) 9 8 (88.9) 
Proteus mirabilis  12 3 (25.0) 4 2 (50.0) 16 5 (31.3) 
Proteus vulgaris  8 3 (37.5) 8 3 (37.5) 16 6 (37.5) 
Providencia species  2 0 (0.0) 5 1 (20.0) 7 1 (14.3) 
Acinetobacter species 6 2 (33.3) 12 5 (41.7) 18 7 (44.4) 
Pseudomonas 
aeruginosa 
24 13 (54.2) 6 3 (50.0) 30 16 (53.3) 
Total  105 50 (47.6) 125 52 (41.6) 230 102 (44.3) 
*Wound vs urine: OR 55.000, 95% CI = 0.8278, 36545; p = 0.0476 OR = odd ratio, CI = confidence interval  
 
Table 2: Prevalence of ESBL production in relation to patients 
 
Organism  In–patient Out–patient  
OR 
 
95 % CI 
 








Escherichia coli 36 16 (44.4) 43 20 (46.5) 0.920 0.378-2.240 1.0000 
Klebsiella  species  29 13 (44.8) 19 8 (42.1) 1.117 0.347-3.595 1.0000 
Citrobacter species  4 2 (50.0) 3 0 (0.0) 7.000 0.224-
219.13 
0.4286 
Enterobacter species  4 3 (75.0) 5 5 (100.0) 0.212 0.007-6.822 0.4444 
Proteus mirabilis  12 4 (33.3) 4 1 (25.0) 1.500 0.116-
19.450 
1.0000 
Proteus vulgaris  6 4 (66.7) 10 2 (20.0) 8.000 0.803-
79.700 
0.1181 
Providencia  species  1 0 (0.0) 6 1 (16.7) 1.222 0.031-
48.244 
1.0000 





23 14 (60.9) 7 2 (28.6) 3.889 0.617-
24.529 
0.2040 
Total  123 60 (48.8) 107 42 (39.3) 1.474 0.872-2.492 0.1833 
OR = odd ratio, CI = confidence interval 
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Table 3: Susceptibility profiles of ESBL producing isolates 
 

















Escherichia coli  (n=36) 2 (5.6) 6 (16.7) 2 (5.6) 0 (0.0) 26 (72.2) 11 (30.6) 6 (16.7) 
 
6 (16.7) 











Citrobacter species  (n=2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 1 (50.0) 0 (0.0) 0 (0.0) 
Enterobacter species  (n=8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 7 (87.5) 1 (12.5) 3 (37.5) 2 (25) 






1 (20.0) 1 (20.0) 
Proteus vulgaris  (n=6) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 3 (50.0) 1 (16.7) 0 (0.0) 0 (0.0) 
Providencia  species  (n=1) 0 (0.0) 1 (100.0) 
 










Acinetobacter species  (n=7) 0 (0.0) 1 (14.3) 1 (14.3) 0 (0.0) 3 (42.9) 1 (14.3) 0 (0.0) 0 (0.0) 
Pseudomonas aeroginosa  
(n=16) 
0 (0.0) 4 (24.0) 0 (0.0) 0 (0.0) 7 (43.8) 2 (12.5) 1 (6.3) 5 (31.3) 
Number tested, AUG= Amoxicillin-clavulanate, CAZ=ceftazidime, CRO=Ceftriaxone, CTX=Cefotaxime, PM=Imipenem, CN=Gentamicin, CIP=Ciprofloxacin, OFX=Ofloxacin. 
Figures in parenthesis are percentages 
 
Table 4: Susceptibility profiles of non–ESBL producing isolates 
 

















Escherichia coli  (n=43) 5 (11.6) 24 (55.8) 16 (37.2) 24 (55.6) 37 (86.0) 19 (44.2) 17 (39.5) 18 (41.7) 
Klebsiella  species  (n=27) 1 (3.7) 7 (25.9) 6 (22.2) 4 (14.8) 22 (81.5) 2 (7.4) 15 (55.6) 15 (55.6) 
Citrobacter species  (n=5) 1 (20.0) 1 (20.0) 1 (20.0) 1 (20.0) 4 (80.0) 0 (0.0) 2 (40.0) 2 (40.0) 
 



































Proteus vulgaris  (n=10) 2 (20.0) 3 (30.0) 6 (60.0) 4 (40.0) 6 (60.0) 5 (50.0) 4 (40.0) 2 (20.0) 
 

















Acinetobacter species  (n=11) 2 (18.2) 6 (54.5) 9 (18.8) 5 (45.5) 7 (63.6) 5 (45.5) 4 (36.4) 4 (36.4) 
 

















Number tested, AUG= Amoxicillin-clavulanate, CAZ=ceftazidime, CRO=Ceftriaxone, CTX=Cefotaxime, PM=Imipenem, CN=Gentamicin, CIP=Ciprofloxacin, OFX=Ofloxacin. 
Figures in parenthesis are percentages 
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[11,17], where CTX–M–15 was reported to 
predominate [11]. CTX–M–15, CTX–M–3 and 
CTX–M–2 have been reported as the 
predominant CTX–M type of ESBL from previous 
studies [11,17,18]. Molecular studies are needed 
to determine which ESBL type predominates in 
our locality as the previous studies in south–west 
geo-political zone of Nigeria. 
 
A total of 102 (44.3 %) of the 230 Gram negative 
bacteria isolates produces ESBL. This is higher 
than the 2.7 %, 15.8 %, 20 % and 28.9 % 
reported in previous studies in Nigeria 
[8,12,18,19]. Previous use of antimi-crobial 
agents, especially cephalosporins and 
fluoroquinolones, has been reported as risk 
factors associated with emergence of ESBL [6,7]. 
Both antimicrobial agents are the drug of choice 
in treating Gram negative bacterial infections [8]. 
Unregulated use of antibiotics and over the 
counter sales of antibiotics without prescription is 
rife in Nigeria [9-11]. The cumulative effect of 
these over time may have been responsible for 
this high prevalence.  
 
There was no significant difference in the 
prevalence of ESBL production between Gram 
negative bacterial isolates recovered from 
wounds and urinary tract infections. Gram 
negative bacteria cause a significant number of 
infections in Nigerian hospitals and represent the 
majority of both wound and urinary isolates, 
which form the largest group of clinical 
specimens received in microbiology laboratories 
[11]. This indicates that unregulated use of 
antibiotics for treating infections from these two 
sites may be rife. Indeed, cephalosporins and 
fluoroquinolones (risk factors associated with 
ESBL production) are used as drugs of choice in 
treating infections caused by Gram negative 
pathogens [8] which may explain the findings in 
this study. 
 
The finding that Gram negative bacteria from 
wound and urine specimens produce ESBL 
agrees with previous reports [5,19]. Enterobacter 
species were the most prevalent producers of 
ESBL generally and from both wounds and 
urinary tract infections as previously reported 
from this study locality [12] and disagrees with 
others which reported Escherichia coli and 
Klebsiella species as the predominant producers 
[20]. The reason for this is unclear. The 
prevalence of ESBL did not differ significantly 
between Gram negative bacteria recovered from 
in–patients and out–patients (p = 0.1833). An 
earlier study from the same facility that consisted 
of bacterial isolates from female reproductive 
tract did not observe higher antibacterial resistant 
among isolates from in–patients compared to 
their out–patient counterparts [21]. However, it 
has been reported that the highest volumes of 
antibiotics are being prescribed and consumed in 
ambulatory care [22] which would have resulted 
in higher prevalence of ESBL among out-patients 
isolates. Thus, the unregulated use of antibiotics 
in the facility may explain the findings in this 
study.  
 
The susceptibility profiles of ESBL-producing 
Gram negative bacteria revealed imipenem to be 
the most active antibacterial agent. Imipenem is 
not affected by ESBL and this may explain the 
finding in this study. Gentamicin and 
fluoroquinolones used in this study were poorly 
active against ESBL producers. Genes coding for 
CTX–M type of ESBL have been reported to be 
associated with plasmids that code for resistance 
to tetracycline, aminoglycosides and quinolones 
[8]. Phenotypically, the CTX–M types of ESBL 
were more prevalent in this study and this may 
explain the poor activity of gentamicin and the 
fluoroquinolones used in this study to ESBL–
producing Gram negative bacteria.  
 
Although amoxicillin–clavulanate, ceftazidime, 
ceftriaxone and cefotaxime showed in vitro 
activity against some ESBL–producing isolates, 
ESBL enzymes have been reported to confer 
resistance to all penicillins and cephalosporins 
[23]. ESBL–mediated resistance is not obvious in 
disc or dilution susceptibility testing but is 
associated with clinical failure [12,13]. This may 
explain the result of their disc susceptibility 
testing results. Susceptibility profiles of non–
ESBL–producing isolates reveal poor to high 
activity while Imipenem was the most active 
antibacterial agent. The finding confirms that 
ESBL–producing Gram negative bacteria are 
more resistant than their non–ESBL–producing 
counter parts.  
 
The limitation of this study is that molecular 
technique was not applied in the evaluation as 
there are some type of ESBL that can only be 
detected by molecular means and not the 




A high prevalence (44.3 %) of ESBL production 
among Gram negative bacteria is reported in this 
study. Enterobacter species were the 
predominant producers of ESBL and ESBL–
producing isolates were more resistant to 
antibacterial agents. Prudent use of antibacterial 
agents is advocated. 
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